Spoken Alpha
BIOVIE INC.
BioVie develops investigational drug therapies for neurological and neurodegenerative disorders and advanced liver disease. The company's lead candidate, bezisterim, is an oral anti-inflammatory agent in clinical trials for Alzheimer's disease, Parkinson's disease, and long COVID.
BIOVIE INC.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add BIVIW, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BIVIW.
$ curl https://api.spokenalpha.com/v1/companies/BIVIWFAQ
Spoken Alpha indexes BIVIW's earnings call transcripts at https://spokenalpha.com/companies/BIVIW. Each call links to attributed speakers and parsed analyst Q&A. BIOVIE INC.'s own investor relations page is at https://investors.bioviepharma.com/overview/default.aspx.